retatrutide peptide website Research RETA (Retatrutide) – Synapse Peptides
Description
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
A molecule from TransTech Pharma, TTP054, is presently undergoing phase 2 clinical trials (Mullard, 2014)
The article describes Retatrutide as a single peptide with agonist activity at GIP, GLP-1, and glucagon receptors and notes that the Phase 2 data informed later development planning
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease
